DeCure's autonomous Respiratory AI scientist is researching a drug-repurposing hypothesis for idiopathic interstitial pneumonia — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleIdiopathic interstitial pneumonia maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for idiopathic interstitial pneumonia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
myeloperoxidase (MPO) — MPO is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet hemdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5MFA · 1.2 Å · ligand PROTOPORPHYRIN IX CONTAINING FE (HEM). Experimental structure, not a prediction.
What the evidence adds up to
Propylthiouracil, at 300 mg/day, was associated with the development of diffuse interstitial pneumonitis in two patients with Graves’ disease after six months or three weeks of treatment. Symptoms and signs improved after the drug was stopped and prednisolone acetate was given. Lymphocyte transformation by phytohemagglutinin was highly stimulated by propylthiouracil. This was the first report of such a complication.
Idiopathic interstitial pneumonias account for roughly one-third of interstitial lung diseases. Their classification has been revised several times, most recently in 2013, but the group remains a source of confusion in clinical practice. The rarity of these diseases and the wide variation in clinical, radiological and pathological descriptions across authors make study and management difficult. Only in 2002 did some consensus on classification begin to emerge.
A phase 2 study tested carboplatin, weekly paclitaxel and bevacizumab in 21 chemotherapy-naïve patients with advanced non-squamous, non-small cell lung cancer complicated by idiopathic interstitial pneumonia. The study was terminated early because of poor accrual. The overall response rate was 61.9% (95% CI, 38.4–81.9), meeting the primary endpoint. Median progression-free survival was 9.69 months (95% CI, 5.78–11.63), median time to treatment failure was 8.21 months (95% CI, 3.75–11.63), and median overall survival was 20.93 months (95% CI, 13.17–29.83). No acute exacerbation of idiopathic interstitial pneumonia or treatment-related death occurred during protocol treatment.
What is still missing is a standard optimal treatment regimen for lung cancer patients with idiopathic interstitial pneumonia. The phase 2 study was limited by poor accrual and a small sample size. No randomised controlled trials have been reported. Patient stratification by subtype of idiopathic interstitial pneumonia, and prospective trials with adequate enrolment, remain absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Internal Medicine · 1984 · 23 citations
AbstractCough productive of sputum, exertional dyspnea, and hypoxemia developed in two patients with Graves' disease after six months (patient 1) or three weeks (patient 2) of treatment with propylthiouracil, 300 mg/day. Chest roentgenograms and transbronchial lung biopsy specimens revealed diffuse interstitial pneumonitis. Lymphocyte transformation by phytohemagglutinin was highly stimulated by propylthiouracil. Symptoms and signs improved after cessation of the drug therapy and administration of prednisolone acetate. These cases represent the first report of a complication of diffuse interstitial pneumonitis induced by propylthiouracil.
Current concepts and dilemmas in idiopathic interstitial pneumonias
AbstractIdiopathic interstitial pneumonias comprise approximately one-third of interstitial lung diseases (also called diffuse parenchymal infiltrative lung diseases). The classification of idiopathic interstitial pneumonias has undergone several revisions since the initial description of 40 years ago, and the most recent version was published in 2013. Although some aspects have been clarified, this group of heterogeneous disorders continues to be a source of confusion and misunderstanding in clinical applications. In this article, we explore several topical themes in the evaluation and management of patients with idiopathic interstitial pneumonias.
Revista Portuguesa de Pneumologia · 2006 · 0 citations · open access
Pneumonias intersticiais idiopáticas – Uma revisão da literatura
AbstractAs pneumonias intersticiais idiopáticas (PII) são um grupo de doenças de difícil estudo e abordagem clínica, devido a vários factores, dos quais se destacam a sua raridade e a enorme discrepância nas descrições dos achados clínicos, imagiológicos e histológicos pelos vários autores. Um dos espelhos desta discrepância é o problema da classificação das várias entidades que constituem este grupo e que apenas em 2002 começou a esboçar algum consenso entre as autoridades na matéria. O objectivo desta revisão é compilar a literatura mais relevante, de modo a facilitar a compreensão de um tema tão complexo. Interstitial idiopathic pneumonias are a group of diseases whose rarity and variety of clinical, radiological and pathological descriptions creates difficulties in study and management. An example of this is the classification method for this group, with only 2002 seeing some consensus. The aim of this article is to review the main literature to contribute to an understanding of this subject.
Japanese Journal of Clinical Oncology · 2024 · 0 citations · open access
Phase II study of carboplatin plus weekly paclitaxel with bevacizumab for non-squamous, non-small cell lung cancer with idiopathic interstitial pneumonia (Hanshin Cancer Group IP002)
AbstractBACKGROUND: There is an increased risk of acute exacerbation of idiopathic interstitial pneumonia when treating patients with advanced non-small cell lung cancer with idiopathic interstitial pneumonia. There is no standard optimal treatment regimen for patients with lung cancer complicated with idiopathic interstitial pneumonia. We aimed to evaluate the efficacy and safety of carboplatin (CBDCA), bevacizumab (Bmab) and weekly paclitaxel (PXT) in patients with idiopathic interstitial pneumonia. METHODS: This phase 2 study involved chemotherapy-naïve patients with advanced non-small cell lung cancer with idiopathic interstitial pneumonia. Patients received CBDCA (area under the curve: 5 on day 1), PXT (70 mg/m2 on days 1, 8 and 15) and Bmab (15 mg/kg on day 1) every 4 weeks. The primary endpoint was the overall response rate. RESULTS: Twenty-one patients were enrolled between January 2013 and October 2018 and received at least one course of the protocol treatment. The study was terminated before enrolling the planned number of patients because of poor accrual. The median patient age was 69 (range: 62-79) years, and 19 (90.5%) patients were men. The overall response rate was 61.9% (95% confidence interval [CI], 38.4-81.9), meeting the primary endpoint. The median progression-free survival, time to treatment failure, and overall survival were 9.69 (95% CI, 5.78-11.63), 8.21 (95% CI, 3.75-11.63) and 20.93 (95% CI, 13.17-29.83) months, respectively. There was no acute exacerbation or treatment-related death during protocol treatment. CONCLUSION: The results indicate that patients with advanced non-squamous, non-small cell lung cancer with idiopathic interstitial pneumonia could be effectively and safely treated using a combination of CBDCA, PXT and Bmab.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
